Proxima provides strategic principal investments, governance advisory, and structured alternative solutions. Build long-term resilience for your digital asset venture.
About the role
We are building out our chemistry function in Boston and hiring a Senior Chemist to drive the chemistry on our pipeline programs. You will own compound design and synthesis for a discovery program from hit identification through lead optimization, working shoulder to shoulder with our Boston biology team. You will also work directly with our ML scientists, pressure-testing what Neo-1 generates against what is actually synthesizable and actually worth making.
What they're looking for
- PhD in organic chemistry
- Roughly 8-12 years of post-PhD experience in medicinal chemistry or chemical biology, with extensive synthetic chemistry experience
- Demonstrated structure-based drug design capability: you have used structures and models to make chemistry decisions that improved potency or selectivity
- Practical computational chemistry skills built through discovery work rather than from a purely computational background
- Biology fluency: you can read a pharmacology package, reason about late-stage pharmacology and translational implications, and hold your own with biologists
- Program experience on enzyme and/or receptor targets (GPCRs, nuclear receptors)
More about this role
Proxima is a frontier AI and data generation company discovering the next generation of proximity therapeutics by making protein interactions programmable. Our platform brings together foundation-model machine learning, a scalable data generation engine, and a partnership track record exceeding $5B in collaborations across the world’s leading biopharma and tech organizations. We’ve recently closed an oversubscribed $80M seed round with an elite group of VCs including DCVC, NVIDIA’s NVentures, AIX, Yosemite among others.
Neo-1 is our all-atom foundation model that combines state-of-the-art structure prediction and molecular generation in a single system. Neo-1 enables rapid exploration of chemical and structural space for high value, previously intractable targets, and in particular unlocks small molecule proximity therapeutics like molecular glues with AI for the first time.
In parallel, we are developing an advanced structural interactomics platform built on proprietary XLMS technology and our Boston lab equipped with next-generation mass spectrometry instrumentation. This platform produces proteome-scale maps of protein interactions and helps identify small molecules that...
Browse similar: Venture capital jobs · Remote jobs